Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MBX by emailGet an email when MBX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MBX, unsubscribe in one click. Privacy
📣 What MBX Says Is Next
fourth quarter of 2026 · “The Company expects to present preclinical data from MBX 6180 at a scientific meeting in the fourth quarter of 2026.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “The Company remains on track to report data from the first cohort of the 12-week MAD (Part C) in Q4 2026.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “Data from the 12-week MAD Part C cohort remain on track for Q4 2026.”
Company press release, May 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MBX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.